Eva Kudova
Czech Academy of Sciences, Czech Republic
Title: SMART steroids: Steroidal molecules as rapid-acting therapeutics
Biography
Biography: Eva Kudova
Abstract
Neurosteroids are compounds synthesized in the nervous tissue from cholesterol, or steroidal precursors from peripheral sources. It is believed that neurosteroids execute their effects by modulating the activity of different membrane receptors, including the glutamatergic ionotropic receptors, e.g. N-methyl-D-aspartate receptors (NMDARs). The NMDARs play an important role in development, synaptic plasticity, learning, and memory, however, abnormal activation of NMDA receptors have been shown to mediate neuronal degeneration/cell death. To find novel potentially beneficial drugs to treat neurological damage or neurodegeneration is one of the most investigated areas in contemporary pharmacology and neuroscience. Therefore, we have designed and synthesized a library of SMART Steroids – Steroidal Molecules As Rapid-acting Therapeutics. SMART steroids are neuroactive molecules, targeting primarily NMDARs, show neuroprotective properties, and minimal side effects in animal models. Our screening pipeline currently covers physicochemical and biological properties like: (i) solubility (DLS); (ii) lipophilicity (logP, logD, ΔGsolv); (iii) patch-clamp recordings from HEK293 cells assessing NMDAR inhibition rates and IC50 values; (iv) Caco-2 assay, (v) treatment of glutamate and NMDA-induced neurotoxicity (survival rate, caspase-3, intracellular calcium levels, ROS); (vi) in vitro growth of postnatal neurons after neurosteroid administration, (vii) models of animal behavior (open field, elevated plus maze, forced swim test, etc.); (viii) PTZ-induced seizures; (ix) paclitaxel-induced peripheral neuropathy; (x) pharmacokinetic properties. Our results indicate that these compounds do afford neuroprotective effect and as such, SMART steroids may be beneficial in treatment of several neurological diseases like epilepsy, neuropathic pain, AD, PD and others. Broad patent portfolio has been developed protecting compounds, production and its use for treatment in neurology etc. (EP 2313424, US 2012071453, EP 2675821, WO2016029888 A1). Supported by grant TE01020028 Center for Development of Original Drugs from the Technology Agency of the Czech Republic and RVO 61388963.